Leukemia, Myeloid, Chronic, BCR-ABL Positive Clinical Trial
Official title:
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance.
The purpose of this study is to determine if low-dose imatinib and nilotinib combination,
will improve treatment results in CML patients with failure, suboptimal response or
intolerance to imatinib therapy.
The hypothesis is that with low-dose imatinib and nilotinib combination, major molecular
response will be achieved in patients not previously obtained with imatinib monotherapy.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment